特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
440733

Frontier Pharma:免疫学の汎用イノベーション - 幅広い治療分野のパイプライン

Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential

出版日: | 発行: GlobalData | ページ情報: 英文 80 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.56円
Frontier Pharma:免疫学の汎用イノベーション - 幅広い治療分野のパイプライン
出版日: 2017年01月05日
発行: GlobalData
ページ情報: 英文 80 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、免疫学の汎用イノベーションについて調査分析し、イノベーション事例、概要、パイプライン製品の評価、プログラムの評価、戦略的統合など、体系的な情報を提供しています。

第1章 目次

第2章 エグゼクティブサマリー

第3章 イノベーション事例

  • 生物製剤の機会が拡大
  • 分子標的の多様化
  • 革新的なファーストインクラス製品 (画期的医薬品) の開発が今も魅力的
  • 規制・償還政策が、ファーストインクラス製品のイノベーションに有利に
  • 持続的なイノベーション

第4章 イントロダクション

  • 治療分野の概要
  • 症状
  • 病因と病態生理
  • 併存疾患と合併症
  • 疫学
  • 治療

第5章 パイプライン情勢の評価

  • 概要
  • パイプライン開発の情勢
  • パイプラインの分子標的
  • 腫瘍学市場とパイプライン間のプログラムの比較分布:治療標的ファミリー別
  • ファーストインクラス汎用パイプラインプログラム
  • ファーストインクラス免疫学製品:フェーズ、分子タイプ、分子標的別
  • ファーストインクラスパイプライン製品の汎用性

第6章 シグナリング (シグナル伝達) ネットワーク、疾患の因果関係、イノベーションの調整

  • シグナル伝達ネットワークの複雑さ
  • シグナル伝達経路とファーストインクラス分子標的の統合
  • ファーストインクラスマトリクスの評価

第7章 ファーストインクラス標的とパイプラインプログラムの評価

第8章 戦略的統合

  • 産業全体のファーストインクラス取引
  • ライセンス取引
  • 共同開発取引
  • 事前取引に関与する/しないファーストインクラスパイプライン製品のリスト

第9章 付録

目次
Product Code: GBIHC430MR

Immunology is one of the largest therapy areas, with a total of 2,145 products in active development, trailing only oncology, infectious diseases and central nervous system disorders in terms of pipeline size. There are a total of 539 immunology pipeline products that act on a first-in-class molecular target, representing 40% of the total immunology pipeline for which the molecular target was disclosed.

Immunology is a therapy area characterized by disorders of the immune system, specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or acute inflammation. Depending on the specific site affected, this can lead to various types of chronic pain and loss of mobility, and have a negative impact on quality of life.

The immune system is highly complex and has a high degree of functional redundancy. For example, the functions of cytokines and chemokines, which serve as endogenous systemic chemical messengers for the immune system, are overlapping and often incompletely characterized. While this presents numerous molecular targets for potential pharmaceutical intervention across multiple diseases, it also creates difficulty in selecting the appropriate target or combination of targets for these drugs. There are a total of 253 distinct first-in-class molecular targets in development, of which 65 were found to be in development across multiple indications. Cytokines and intracellular signal transducers were strongly represented amongst the most promising versatile first-in-class molecular targets.

Between 2006 and 2016, a total of 497 licensing deals and 433 co-development deals in the immunology therapy area were identified as having been completed, with a combined aggregate value of US$46 billion. This high level of deal-making activity is indicative of a strong willingness on the part of pharmaceutical companies to engage in strategic consolidations in order to mitigate some of the risks associated with drug development in the immunology therapy area.

The report "Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential" helps you to understand the current standard of treatment across these markets, and what lessons can be learned by companies seeking to innovate and build on these products, also helps to identify current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options and leading products and companies within the market, as well as key unmet needs, in order to gain a competitive understanding of gaps in the market. Additionally, it will insights to review key pipeline trends by analyzing therapies by stage of development, molecule type and molecular target, and identify key trends regarding innovation within each segment and identify promising first-in-class pipeline assets that have had no prior involvement in licensing or co-development deals, and are therefore potentially suitable for in-licensing.

1 Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Executive Summary

  • 2.1. Large Therapy Area Characterized by a High Degree of Pathophysiological Crossover
  • 2.2. Strong Pipeline Shows High Level of Versatile Innovation
  • 2.3. Substantial Deal Making Activity Observed over the Past Decade

3. The Case for Innovation in the Immunology Market

  • 3.1. Growing Opportunities for Biologic Products
  • 3.2. Diversification of Molecular Targets
  • 3.3. Innovative First-in-Class Product Developments Remain Attractive
  • 3.4. Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
  • 3.5. Sustained Innovation

4. Introduction

  • 4.1. Therapy Area Introduction
  • 4.2. Symptoms
  • 4.3. Etiology and Pathophysiology
    • 4.3.1. Innate Immunity
    • 4.3.2. Adaptive Immunity
    • 4.3.3. The Role of Cytokines
    • 4.3.4. Autoimmunity
    • 4.3.5. Etiologic Factors for Autoimmunity and Allergies
    • 4.3.6. Conclusion
  • 4.4. Co-morbidities and Complications
  • 4.5. Epidemiology
  • 4.6. Treatment
    • 4.6.1. Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
    • 4.6.2. Glucocorticoids
    • 4.6.3. Biologics and Targeted Therapies

5. Pipeline Landscape Assessment

  • 5.1. Overview
  • 5.2. Pipeline Development Landscape
  • 5.3. Molecular Targets in the Pipeline
  • 5.4. Comparative Distribution of Programs between the Oncology Market and Pipeline by Therapeutic Target Family
  • 5.5. First-in-Class and Versatile Pipeline Programs
  • 5.6. First-in-Class Immunology Products by Phase, Molecule Type and Molecular Target
  • 5.7. Versatility of First-in-Class Pipeline Products

6. Immunology Signaling Network, Disease Causation and Innovation Alignment

  • 6.1. Complexity of Signaling Networks
  • 6.2. Signaling Pathways and First-in-Class Molecular Target Integration
  • 6.3. First-in-Class Matrix Assessment

7. First-in-Class Target and Pipeline Program Evaluation

  • 7.1. Pipeline Programs Targeting Toll-Like Receptors 3, 6 and 8
  • 7.2. Pipeline Programs Targeting Spleen Tyrosine Kinase
  • 7.3. Pipeline Programs Targeting IL-7R
  • 7.4. Pipeline Programs Targeting C-C Chemokine Receptor Type 6
  • 7.5. Pipeline Programs Targeting P2RX7
  • 7.6. Pipeline Programs Targeting ITK
  • 7.7. Pipeline Programs Targeting IRAK4
  • 7.8. Pipeline Programs Targeting Orai1
  • 7.9. Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5
  • 7.10. Conclusion

8. Strategic Consolidations

  • 8.1. Industry-Wide First-in-Class Deals
  • 8.2. Licensing Deals
    • 8.2.1. Deals by Region, Year and Value
    • 8.2.2. Deals by Stage of Development and Value
    • 8.2.3. Deals by Molecule Type and Value
    • 8.2.4. Deals by Molecular Target and Value
  • 8.3. Co-development Deals
    • 8.3.1. Deals by Region, Year and Value
    • 8.3.2. Deals by Stage of Development and Value
    • 8.3.3. Deals by Molecule Type and Value
    • 8.3.4. Deals by Molecular Target and Value
  • 8.4. List of First-in-Class Pipeline Products with and Without Prior Deal Involvement

9. Appendix

  • 9.1. Abbreviations
  • 9.2. References
  • 9.3. Research Methodology
    • 9.3.1. Data integrity
    • 9.3.2. Innovative and meaningful analytical techniques and frameworks
    • 9.3.3. Evidence based analysis and insight
  • 9.4. Secondary Research
    • 9.4.1. Market Analysis
    • 9.4.2. Pipeline Analysis
    • 9.4.3. Licensing and Co-development Deals
  • 9.5. Contact Us
  • 9.6. Disclaimer

List of Tables

  • Table 1: Versatile Innovation in Immunology, Global, Epidemiology of Inflammatory Immunological Disorders, 2015
  • Table 2: Versatile Innovation in Immunology, Global, Toll-Like Receptors and their Known Ligands, 2016
  • Table 3: Versatile Innovation in Immunology, Global, Key Features of TLR3, 2016
  • Table 4: Versatile Innovation in Immunology, Global, Key Features of TLR6, 2016
  • Table 5 Versatile Innovation in Immunology, Global, Key Features of TLR8, 2016
  • Table 6: Versatile Innovation in Immunology, Global, Key Features of Syk, 2016
  • Table 7: Versatile Innovation in Immunology, Global, Key Features of IL-7R, 2016
  • Table 8: Versatile Innovation in Immunology, Global, Key Features of C-C Chemokine Receptor Type 6, 2016
  • Table 9: Versatile Innovation in Immunology, Global, Key Features of P2RX7, 2016
  • Table 10: Versatile Innovation in Immunology, Global, Key Features of ITK, 2016
  • Table 11: Versatile Innovation in Immunology, Global, Key Features of IRAK4, 2016
  • Table 12: Versatile Innovation in Immunology, Global, Key Features of Orai1, 2016
  • Table 13: Versatile Innovation in Immunology, Global, Key Features of Tumor Necrosis Factor Receptor Superfamily Member 5 , 2016

List of Figures

  • Figure 1: Versatile Innovation in Immunology, US, Innovation Trends in Product Approvals, 1987-2014
  • Figure 2: Versatile Innovation in Immunology, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013
  • Figure 3: Versatile Innovation in Immunology, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area and Breakdown of Immunology Pipeline by Indication, 2016
  • Figure 4: Versatile Innovation in Immunology, Global, Pipeline for Immunology by Stage of Development and Molecule Type, 2016
  • Figure 5: Versatile Innovation in Immunology, Global, Pipeline for Immunology by Molecular Target, 2016
  • Figure 6: Versatile Innovation in Immunology, Global, Pipeline and Marketed Products for Immunology by Molecular Target Category, 2016
  • Figure 7: Versatile Innovation in Immunology, Global, Overall Pharmaceutical Industry First-in-Class Pipeline by Therapy Area and Breakdown of Immunology First-in-Class Pipeline by Indication, 2016
  • Figure 8: Versatile Innovation in Immunology Therapeutics Market, Global, First-in-Class Pipeline for Immunology by Stage of Development and Molecule Type, 2016
  • Figure 9: Versatile Innovation in Immunology, Global, First-in-Class Pipeline for Immunology by Molecular Target, 2016
  • Figure 10: Versatile Innovation in Immunology, Global, Pipeline for Immunology by First-in-Class Status and Molecular Target Class, 2016
  • Figure 11: Versatile Innovation in Immunology, Global, Distribution of First-in-Class and Established Products by Stage of Development (%), 2016
  • Figure 12: Versatile Innovation in Immunology, Global, Distribution of First-in-Class and Established Products by Molecular Target Class (%), 2016
  • Figure 13: Versatile Innovation in Immunology, Global, First-in-Class Immunology Pipeline Products by Number of Indications, 2016
  • Figure 14: Versatile Innovation in Immunology, Global, Pipeline for Key Immunology Indications by Molecular Target, 2016
  • Figure 15: Versatile Innovation in Immunology, Global, Versatile Pipeline for Immunology by Stage of Development and Molecule Type, 2016
  • Figure 16: Versatile Innovation in Immunology, Global, Versatile First-in-Class Pipeline Immunology by Molecular Target, 2015
  • Figure 17: Versatile Innovation in Immunology, Global, First-in-Class Pipeline for Immunology by Versatile Status and Molecular Target Class, 2016
  • Figure 18: Versatile Innovation in Immunology, Global, First-in-class Pipeline for Immunology Indications (Part 1), 2016
  • Figure 19: Versatile Innovation in Immunology, Global, First-in-class Pipeline for Immunology Indications (Part 2), 2016
  • Figure 20: Versatile Innovation in Immunology, Global, First-in-class Pipeline for Immunology Indications (Part 3), 2016
  • Figure 21: Versatile Innovation in Immunology, Global, First-in-class Pipeline for Immunology Indications (Part 4), 2016
  • Figure 22: Versatile Innovation in Immunology, Global, First-in-Class Matrix, 2016 (part 1)
  • Figure 23: Versatile Innovation in Immunology, Global, First-in-Class Matrix, 2016 (part 2)
  • Figure 24: Versatile Innovation in Immunology, Global, First-in-Class Matrix, 2016 (part 3)
  • Figure 25: Versatile Innovation in Immunology, Global, Pipeline Programs Targeting TLR3, 2016
  • Figure 26: Versatile Innovation in Immunology, Global, Pipeline Programs Targeting TLR6, 2016
  • Figure 27: Versatile Innovation in Immunology, Global, Pipeline Programs Targeting TLR8, 2016
  • Figure 28: Versatile Innovation in Immunology, Global, Pipeline Programs Targeting Syk, 2016
  • Figure 29: Versatile Innovation in Immunology, Global, Pipeline Programs Targeting IL-7R, 2016
  • Figure 30: Versatile Innovation in Immunology, Global, Pipeline Programs Targeting C-C Chemokine Receptor Type 6, 2016
  • Figure 31: Versatile Innovation in Immunology, Global, Pipeline Programs Targeting P2RX7, 2016
  • Figure 32: Versatile Innovation in Immunology, Global, Pipeline Programs Targeting ITK, 2016
  • Figure 33: Versatile Innovation in Immunology, Global, Pipeline Programs Targeting IRAK4, 2016
  • Figure 34: Versatile Innovation in Immunology, Global, Pipeline Programs Targeting Orai1, 2016
  • Figure 35: Versatile Innovation in Immunology, Global, Pipeline Programs Targeting Tumor necrosis factor receptor superfamily member 5 , 2016
  • Figure 36: Versatile Innovation in Immunology, Global, Licensing Deals by Stage of Development, 2006-2015
  • Figure 37: Versatile Innovation in Immunology, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Status ($m), 2006-2015
  • Figure 38: Versatile Innovation in Immunology, Global, Licensing Deals by Region, Value and Year, 2006-2016
  • Figure 39: Versatile Innovation immunology, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
  • Figure 40: Versatile Innovation in Immunology, Global, Licensing Deals by Molecule Type, 2006-2016
  • Figure 41: Immunology, Global, Licensing Deals by Molecular Target, 2006-2016
  • Figure 42: Versatile Innovation in Immunology, Global, Licensing Deals Valued Above $100m, 2006-2016
  • Figure 43: Versatile Innovation in Immunology, Global, Co-development Deals by Region, Value and Year, 2006-2016
  • Figure 44: Immunology, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
  • Figure 45: Versatile Innovation in Immunology, Global, Co-development Deals by Molecule Type, 2006-2016
  • Figure 46: Versatile Innovation in Immunology, Global, Co-development Deals by Molecular Target, 2006-2016
  • Figure 47: Versatile Innovation in Immunology, Global, Co-development Deals Valued Above $100m, 2006-2016
  • Figure 48: Versatile Innovation in Immunology, Global, List of First-in-Class Pipeline Products with and Without Prior Deal Involvement, 2016
  • Figure 49: Versatile Innovation in Immunology, Global, List of First-in-Class Pipeline Products with and Without Prior Deal Involvement, 2016
  • Figure 50: Versatile Innovation in Immunology, Global, List of First-in-Class Pipeline Products with and Without Prior Deal Involvement, 2016
  • Figure 51: Versatile Innovation in Immunology, Global, List of First-in-Class Pipeline Products with and Without Prior Deal Involvement, 2016
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.